0000950170-23-022775.txt : 20230517 0000950170-23-022775.hdr.sgml : 20230517 20230517165842 ACCESSION NUMBER: 0000950170-23-022775 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230515 FILED AS OF DATE: 20230517 DATE AS OF CHANGE: 20230517 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Yeramian Patrick D CENTRAL INDEX KEY: 0001358266 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-41199 FILM NUMBER: 23932571 MAIL ADDRESS: STREET 1: 1815 PARKSIDE CIRCLE SOUTH CITY: BOCA RATON STATE: FL ZIP: 33486 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Amylyx Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001658551 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 464600503 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 43 THORNDIKE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02141 BUSINESS PHONE: 617-683-0917 MAIL ADDRESS: STREET 1: 43 THORNDIKE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02141 4 1 ownership.xml 4 X0407 4 2023-05-15 0001658551 Amylyx Pharmaceuticals, Inc. AMLX 0001358266 Yeramian Patrick D C/O AMYLYX PHARMACEUTICALS, INC. 43 THORNDIKE STREET CAMBRIDGE MA 02141 false true false false Chief Medical Officer true Common Stock 2023-05-15 4 M false 2201 0.37 A 210618 D Common Stock 2023-05-15 4 M false 9764 6.88 A 220382 D Common Stock 2023-05-15 4 S false 11965 29.0312 D 208417 D Stock Option (right to buy) 0.37 2023-05-15 4 M false 2201 0 D 2029-03-18 Common Stock 2201 15404 D Stock Option (right to buy) 6.88 2023-05-15 4 M false 9764 0 D 2031-02-21 Common Stock 9764 33770 D These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 14, 2022. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.00 to $29.19. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. As of the date of this filing, 2,201 shares subject to the option are vested and exercisable. 15,404 shares subject to such option vest and become exercisable in substantially equal monthly installments until November 26, 2023. As of the date of this filing, 13,746 shares subject to the option are vested and exercisable. 23,600 shares subject to such option vest and become exercisable in substantially equal monthly installments until December 19, 2023. /s/ Joshua B. Cohen, as Attorney in Fact 2023-05-17